The Canadian Generic Pharmaceutical Association (CGPA) has released a report detailing what it calls the failure of brand-name drug companies to spend at least 10% of Canadian revenues on R&D. The report draws its information from the latest report of the Patented Medicines Prices Review Board. It shows that members of Canada's Research-Based Pharmaceutical Companies (Rx&D) spent 6.6% of revenues in 2012 with outlays on basic research dropping 30.5% between 2011 and 2012....